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Abstract. Muscular dystrophy (MD) describes generalized progressive mus-
cular weakness due to the wasting of muscle fibers. The progression of the
disease is affected by known immunological and mechanical factors, and possi-
bly other unknown mechanisms. These dynamics have begun to be elucidated
in the last two decades. This article reviews mathematical models of MD that
characterize molecular and cellular components implicated in MD progression.
A biological background for these processes is also presented. Molecular ef-
fectors that contribute to MD include mitochondrial bioenergetics and genetic
factors; both drive cellular metabolism, communication and signaling. These
molecular events leave cells vulnerable to mechanical stress which can activate
an immunological cascade that weakens cells and surrounding tissues. This
review article lays the foundation for a systems biology approach to study MD
progression.
1. Introduction
Muscular dystrophy (MD) describes generalized progressive muscular weakness
due to the wasting of muscle fibers. While this is an umbrella term used to describe
a wide range of muscle wasting diseases, the two types that have been most exten-
sively mathematically modeled are Duchenne’s (DMD) and Becker’s (BMD) [23,51],
with DMD being the most common childhood form of MD. Males affected by this
X-linked recessive disorder have an average life expectancy in the mid-twenties, typ-
ically becoming fully wheelchair dependent by their teens [15]. MD leaves striated
muscle cells with reduced contractile abilities, leading to a wide range of phenotypic
expression in patients from fatigue to drooping eyelids.
Previous research attributes pathogenesis of DMD and BMD to either absent
or partial forms of the dystrophin protein [43]. From a cellular perspective, the
basic contractile unit of the muscle is the sarcomere. The dystrophin protein is
located between the sarcolemma, the outer membrane of the sarcomere, and outer
layer of myofilaments, providing a scaffold for muscular contraction. Weakness
typically begins in extremity muscles, propagating in a proximal–distal direction,
until ultimately affecting the diaphragmatic muscles responsible for breathing [10,
15]. Hypertrophy of cardiac muscle cells is an additional complication associated
with both DMD and BMD. The loss of function associated with both typically leads
to premature death [16].
Epidemiological impacts of MD remain difficult to pinpoint definitively. Each
subset of MD contains its own range and pattern of pathogenesis and progression.
We can further classify subsets of MD in (ordered in decreasing rates of prevalence):
dystrophinopathies, laminopathies, dystroglycanopathies, sarcoglycanopathies, and
alternative congenital forms [4, 70]. In the United States, dystrophinopathies have
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a prevalence of about 15 cases per 100,000 people [81]. The following list describes
the rates of prevalence of MD per 100,000 cases in Northern England [70]:
(1) With respect to dystrophinopathies that manifest as dystrophin absence or
deficiency, DMD and BMD have been most extensively studied. Incidence
of dystrophinopathies is about 8.5.
(2) Laminopathies, dystroglycanopathies,and sarcoglycanopathies are typically
classified as Limb-Girdle MD (LGMD). The prevalence rate is about 2.
(3) Collagen VI deficiencies that take form in Ullrich Congenital MD (UCMD,
also known as Ullrich Scleroatonic MD) have a prevalence rate around 0.13.
(4) Most alternative congenital forms have rates below one.
The goal of this paper is to offer a survey of quantitative research in MD, as
well as identifying opportunities for quantitative research that are yet to be ex-
plored. This paper is organized as follows: Section 2.1 examines gene regulatory
networks and their applications in genes correlated with MD, since most types of
MD are believed to have genetic origin [43]. The genes implicated in MD have func-
tions in numerous biological processes, thus obscuring a univocal characterization
of MD pathogenesis. As a consequence, many of these genes affect the normal cell
life/death cycle [73].
Section 2.2 explores mitochondrial and genetic targets that have been identi-
fied as major players responsible for the exacerbation of molecular dynamics that
contribute to degenerative processes such as apoptosis [93] and fibrosis [24, 102];
we explain in this section the distinction between self-induced and peer-induced
apoptosis.
Section 3.1 presents the interplay of molecular dynamics that impacts immuno-
logical processes. In certain MDs, chronic immune activation leads to a cycle of
damage-regeneration that perpetuates disease; as a result, muscle cells are replaced
by fibrous and adipose tissue [23, 60]. Section 3.2 explores the mechanical and im-
munological dynamics of muscle cells. Cyclic immunological activation purported
by mechanical stress is associated with coexisting restorative and degenerative pro-
cesses in muscle cells; immunological processes act both as starters and finishers of
apoptosis. CD8+ (cytotoxic T-cells) initiate apoptosis in compromised cells, and
the cellular remains of apoptosis are disposed of by macrophages.
2. Molecular Models
2.1. Genetic. Single nucleotide polymorphisms (SNPs) and their associated gene
targets have been implicated in MD (Table 1). Publicly available databases can be
used to investigate each SNP’s related genes, proteins, and pathways (e.g. SNPedia
[17], OMIM [5], and 1000 Genome Project [20]).
Gene regulatory networks (GRNs) can provide insight regarding subtleties in
disease development; graph theoretic models like Boolean Networks [61], Bayesian
graphs [29], and Petri Net [36] have emerged as important tools for understanding
and reconstructing GRNs. To develop models of GRNs, researchers may employ
database like OMIM [5] or computer programs like Snoopy [79] that use experimen-
tal genetic expression data to reconstruct such networks. GRNs can then be studied
to find nodes that have more parent genes, are up-regulated or down-regulated by
parent genes, affect more downstream genes, or express more often by different but
related diseases like MDs. For time dependent data or complex processes, though,
directed graphs may be impossible to construct. Instead continuous models like
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Figure 1. A regional representation of MD type and correspond-
ing gene SNP in a muscle cell.
dynamic Bayesian networks [69] and temporal Bayesian classifiers [98] can be con-
structed. Although continuous models are unable to answer qualitative questions
about the GRN, continuous models can estimate quantitative values. Lack of data
hampers continuous models ability to explain large complex GRNs. A continuous
model of a GRN involving DMD, LGMD2C, and LGMD2E was constructed by
Tucker et al. (2006) [98] using temporal Bayesian classifiers; the model predicts
that genes Dlk1, Dusp13, and Casq2 play a part in all three MDs and should be
studied further as a possible influence of MD pathogenesis.
In this section we identify the mechanisms associated to the SNPs listed in Table
1. Since not all these pathways have been modeled quantitatively, this section
offers opportunities for systems biology exploration. Fig 1 shows the location in
the cell of each protein product associating with genes containing SNPs implicated
in MD. It illustrates the extracellular and intracellular domains of a muscle cell,
relating proteins embedded within and associated with the nucleus, the dystrophin-
glycoprotein complex (DGC) and the extracellular matrix (ECM). The nuclear
outer membrane (OM) is an integral part of the rough ER (Fig 1). Destabilized
lamina release proteins that diffuse along the OM to the ER.
A and C type lamins (Fig 1) provide structural support within the nuclear mem-
brane and nuclear interior (NI); these are encoded by the gene LMNA (SNPs, Table
1) [62]. Structural deficiencies can cause deficits in gene expression, metabolic sig-
naling within the rough endoplasmic reticulum (ER), and cell cycle control. The ER
is a metabolic highway – with regards to MD, an important target as one featured
pathway includes the release of calcium during contraction cycles in muscles [80].
PABPN1 (Polyadenylate-binding nuclear protein 1) is responsible for the post–
transcriptional modification of mRNA and long non-coding RNAs (lncRNAs) within
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SNPs Gene Target MD
rs28928901 LMNA EDMD, LGMD
rs104894466 PABPN1 OPMD
rs28937902 rs28937903 FKRP LGMD
rs28937904 rs28937900
rs28937905 rs28937901
rs2296949 POMT1 LGMD
rs28933096 LAMA2 LAMA2 Congenital Type MD
rs28937597 MYOT LGMD
rs1800278 DMD DMD, BMD
rs28933693 rs28933694 SGCA LGMD
rs28936383 rs28936384 SGCB LGMD
rs28936385 rs28936386
rs1042917 rs2839110 COL6A2 UCMD
rs1131296 rs2270669 COL6A3 UCMD
Table 1. SNPs Implicated in MD. SNP IDs correspond to SNPe-
dia.com [17]
the nucleus, though its cytoplasmic function remains unknown (SNPs, Table 1).
While expressed at high levels in all tissues, mutations are associated with Ocu-
lopharyngeal MD (OPMD), pathology is strictly localized to muscles [96]. One
pathway, p53 (Fig 1), is an apoptotic determiner with presence attributed to the
expression of the gene PABPN1 [11].
The extent of apoptosis in MD pathogensis is variable among types of MD.
In DMD and BMD, apoptosis occurs prior to necrosis, which is initiated after
changes in muscle histology. Apoptotic events persist throughout disease progres-
sion. Determining deficits which trigger apoptotic events is difficult; MD SNPs
have been implicated in apoptotic promotion, though variable among different MD
types [11,32,95]. Nuclear apoptotic targets also include A lamins as well as LAP2α
(Lamina-associated polypeptide 2) and LAP2β. Depletion of caspase 6, necessary
for cleavage of A lamins during apoptosis, is associated with delayed or fully inhib-
ited apoptosis. A lamin degradation is required for timely apoptosis [1, 28].
Most common within the nuclear inner membrane (IM) is the protein emerin
encoded by the gene EMD; partial or absent forms of emerin are associated with
Emery-Dreifuss MD (EDMD). Mutant A or C type lamins results in the diffusion
of improper proteins like emerin in EDMD cells, reacting with ER proteins and
hijacking these metabolic pathways [80, 83, 97]. Mature A lamins bind to emerin
as well as cytoskeletal proteins actin and titin (Fig 1). With regards to EDMD,
deficient emerin only leads to skeletal and heart muscle defects [83,92].
Intracellular FKRP (SNPs, Table 1) expression has been found in the perinu-
cleus, the ER, Golgi cisernae [14]; extracellular expression has been found in the
sarcolemma and between myofibrils. FKRP coordinates with putative glycosyl-
transferases (GT) or phosphotransferases (PT) to assist in the packaging of dystro-
glycan (DG) proteins, encoded by the gene DAG1, as they move to the sarcolemma.
α-DG hypoglycosylation is the precursor interaction between the actin cytoskele-
ton and components of the ECM. α-DG O-glycosylation is required for extracellular
expression of α-DG and again in muscles (Fig 1) [4, 13]. Overexpression of FKRP
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inhibits maturation of α and β-DG, post-translation [27]. DG defects are associ-
ated with six genes that encode for putative GT or PT; two of which are POMT1
(SNPs, Table 1) and FKRP (SNPs, Table 1). POMT1 works with the POMT2 gene
product to build a protein complex that enables protein O-mannosyltransferase ac-
tivity [22]. POMT1 mutant genes are associated with limb girdle type 2K with
mental retardation as well as congenital MD. Mutations in POMT1 are also asso-
ciated with an abnormal α-DG pattern in the muscle [4, 25,34,55].
Laminin-α2 is encoded by the LAMA2 (SNPs, Table 1) gene; it’s localized to
striated muscle and Schwann cells. Laminin-2, also referred to as merosin, engages
with the DGC through binding to α-1-syntrophin, a calcium pump [104], and the
α7β1 integrin complex, a cell surface receptor (Fig 1). Though the overexpression
of α7β1 integrin in mice models with deficient levels of laminin-α2 does result in
a milder MD phenotype, deletion of α7β1 integrin fails to affect mice models of
laminin-α2 deficient MD. This suggests overlapping functions of proteins within
the DGC and ECM [31,37].
Myotilin (Myo and Titin Immunoglobulin Domain protein) and laminin-α2 form
complexes indirectly with dystrophin (Fig 1). Encoded by MYOT (Table 1), my-
otilin mitigates sarcomere formation; MYOT defects are associated with LGMD1A
[4, 84]. With regards to laminin-α2, α-DG binds to α-2 laminin in the ECM while
β-DG binds to dystrophin in the transmembrane [94].
The dystrophin protein, encoded by DMD (Table 1) [43], acts as a scaffold in a
subsarcolemmal space protein complex for muscle cells; dystrophin binds to actin,
bridging the extracellular and intracellular domains with the cytoskeleton of the
muscle cell (Fig 1) [82]. Absent or partial forms of dystrophin uncouples the DGC;
mechanical stress aside, this also disrupts cellular communication [35,54,105].
Sarcoglycan (SG) defects in MD are encoded by the genes SGCA (SNPs, Table
1) and SGCB (SNPs, Table 1); these encode for the sarcolemma proteins α-SG
and β-SG that stabilize muscle fiber membranes (Fig 1). Mutant SGCA is res-
cued by inhibition of proteasome-mediated, ER-associated degradation (ERAD) of
mannosidase I [8]. A compromised sarcoglycan complex is linked with LGMD; his-
tological analysis reports aggregates of peripheral mitochondrial accumulation as
well as increased, abnormal, levels of serum creatine kinase [86].
Collagen VI is a common ECM protein, with deficiencies associated with COL6A1,
COL6A2 (SNPs, Table 1), and COL6A3 (SNPs, Table 1) gene defects (Fig 1).
UCMD is caused by COL6A2 and COL6A3 mutations. Histological analysis of
UCMD muscle reveals an increased number of internal nuclei as well as an observ-
able dystrophic pattern in muscle biopsy samples collected; lax and hyper-flexible
joints experienced by patients also result in higher propensities for eccentric con-
tractures (Section 3.2 ) and myosclerosis. Collagen VI ECM mutations also affect
the PI3K-Akt signaling pathway (Figure 1), which has immunological applications
(Section 3.1 ) [7, 18].
Models for cell motility that integrate cytoskeletal molecular interactions within
models for muscular contraction are needed to shed light on genotype to pheno-
type interactions. With regards to cell cycle control, mechanical models for the
assembly and reassembly of the nucleus during mitosis will be important in better
understanding the consequences of lamin deficits in MD (Section 3.2 ).
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With a need to relate discrepancies in phenotypic severity with genotype mu-
tations, graph theoretic models have emerged as important tools. SNPs associ-
ated with MD provide data for building gene regulatory networks. Gene, protein
and metabolic regulatory networks require the integration of affiliate pathways and
mechanisms within any future mathematical models.
2.2. Mitochondrial. The distinct role of dystrophin in DMD and BMD’s patho-
genesis and progression remains unknown; despite devastating consequences in
its absence, healthy skeletal muscle expresses a mere 0.002% of the dystrophin
gene [44]. This requires the examination of alternative factors that lead to similar
devastating MD phenotypes [38,45].
Poorly regulated mitochondria have been implicated in DMD and BMD [82].
Mitochondria produce ATP, which is the currency for sarcomere contraction. In a
single cell, there can be hundreds of mitochondria; these organelles are responsible
for far more than ATP synthesis. Mitochondria synthesize protein encoded in mi-
tochondrial DNA (mtDNA) in addition to dividing independently as needed inside
the cell. mtDNA is vulnerable to mutations that perpetuate the mitochondrial
cascade, with rates up to ten times higher than nuclear DNA mutation [56,57].
Mitochondrial proteins like calmitine also regulate the balance of bound and free
calcium in the mitochondrial matrix [65]; healthy levels of free calcium initiate ox-
idative phosphorylation [33]. Heron’s (1995) [64] research noted defects in genes
such as C57 BL 6J dy/dy, attributed to expression of similar DMD phenotypes,
such as in mice muscle cell necrosis. Furthermore, both mice models of disease also
shared calmitine defiencies. Calmitine is the only mitochondrial protein responsible
for binding to calcium, whose expression is contained regionally in the mitochon-
drial matrix of skeletal fast twitch muscle fibers. These deficits are responsible for
higher calcium levels, ultimately activating the mitochondrial cascade attributed to
DMD progression. Given DMD’s and mitochondrial myopathies’ maternal inheri-
tance, Heron’s molecular models provide a basis for MD mitochondrial modeling,
especially with regards to MD pathogenesis and progression [64].
Mitochondria’s shape, number, and energy processing power are constantly in
flux; mitochondrial dynamics alternate between fusion or fission. Tam et al. (2013)
[93] produced a stochastic and probabilistic model examining rates of fusion-fission
that would optimize mitochondrial function and minimize clonal expansion in neigh-
boring mitochondria. This model classifies fusion-fission events in mitochondria
using the following criterion:
(1) Fusion events feature nucleoid exchange between mitochondria; one is emp-
tied out to the other and marked for degradation.
(2) Fission sites appear close to the fusion event, regionally containing original
nucleoid distributions from precursor mitochondria.
(3) Healthy fission features low levels of exchange of nucleoids, with only mi-
tochondrial matrix contents being mixed.
(4) Larger and longer mitochondria have higher propensities for fission, and
smaller ones are more likely to fuse.
The initial conditions in this model feature aR,0, the propensity for nucleoids
to replicate as well as afus,the propensity for mitochondrial fusion. All other
propensities are computed afterwards, as shown in Table 2. Protective nuclear
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Propensity Propensity equations
Upregulated propensity for nu-
cleoid replication due to higher
ratio of mutant mtDNA
aR,del = aR,0
(
rmax
(
1− R
m
W
Kmretro +R
m
W
)
+ 1
)
Propensity for mitochondrial
autophagy
aD,mito = kDNMito
Propensity for mitochondrial
fission
afis,i = VF,max
(Wi +Mi)
n
KnF + (Wi +Mi)
n
Table 2. Propensity Equations for Tam et al. (2013) [93] where
rmax + 1 - is the maximum copy number for amplification of
mtDNA, NMito - is the number of mitochondria in a cell at a given
time kD - the rate of autophagy, and VF,max - is the maximum
propensity of fission.
retrograde signaling could rescue the mitochondrial cascade through the promo-
tion of mitochondrial nucleoid replication propensity up to sixteen times the basal
rate, increasing stochasticity by neutralizing clonal mutant aggregation. Benefits
of nuclear retrograde signaling are limited by rates of fusion-fission. Within this
simulation, rate of mitochondrial fusion-fission plays a significant role in clonal
expansion. Slow exchanges of mtDNA result in homoplasmy, where intervention-
ist retrograde signaling could compound the issue by increasing rate of nucleoid
replication. Higher rates of fusion-fission result in a heteroplasmic steady state; in-
creasing levels of mitochondria in cells mix nucleoids faster. These patterns persist
regardless of mitochondrial presence in the cell or their replication parameters. A
cytoskeletal, cellular model that considers mitochondrial movement independent of
fusion-fission, as well as mitochondrial morphology in a differentiated cell context,
is needed to further conclude potential therapeutic benefits of retrograde signal-
ing [93].
Byproducts of mitochondrial metabolism include small amounts of electrons that
leak from inner membrane complexes and attach themselves to oxygen, forming free
radicals called reactive oxidative species (ROS). In a healthy immune response, free
radicals such as superoxide and nitric oxide are produced by macrophages for de-
struction of foreign species. Small amounts of the free radical superoxide produced
by the mitochondrion are neutralized by antioxidant enzymes such as superoxide
dismutase. Mutated mtDNA leak more ROS in a degenerative, mitochondrial cas-
cade essentially poisoning vulnerable cells through ROS release [56,57].
Intrinsic apoptosis results from a stressed cellular response. Severe ROS damage
can result in cellular necrosis whereas the release of cytochrome c to the cytosol
from the inner membrane of the mitochondria triggers intrinsic apoptosis. Depo-
larization in MOMP (mitochondrial outer membrane permeabilization) in stressed
cells triggers the MOMP cascade. MOMP stress markers in survival-apoptotic dy-
namics feature members of the Bcl-2 protein family and BH-3 only proteins. [30,77].
When triggered by MOMP, mitochondria release cytochrome c and Smac (second
mitochondrial-derived activator of caspases) into the cell’s cytosol. By binding with
XIAPs (x-linked inhibitors of apoptosis), Smac allows for cytochrome c, Apaf-1,
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Fusseneger et al. Equations [30] Variables
d[RL]T
dt
= bL − µ[RL]T [RL] - Concentration of FAS-FAS ligand
complex.
d[R]T
dt
= bR − µ[R]T [R] - Concentration of FAS receptor.
d[F ]
dt
= bF − 2rF − µ[F ] [F ] - Concentration of FADD protein.
d[RL.F2]T
dt
= rF − µ[RL.F2]T [RL.F2] - Concentration of FAS-FASL-
FADD complex.
d[Cc]
dt
= rc − rA1 − µ[Cc] [Cc] - Concentration of cytosolic cy-
tochrome c.
d[Al]T
dt
= bA1 − µ[A1]T [A1] - Concentration of Apaf-1 protein.
d[A1.Cc]
dt
= rA1 − µ[A1.Cc] [A1.Cc] - Concentration of Apaf-1-
cytochrome c complex.
d[C8z]
dt
= b8 − 2r8zal − µ[C8z] [C8z] - Concentration of procaspase-8.
d[C9z]
dt
= b9 − 2r9zal − µ[C9z] [C9z] - Concentration of procaspase-9.
d[C8a]
dt
= 2r8zal − µ[C8a] [C8a] - Concentration of active caspase-8.
d[C9a]
dt
= 2r9zal − µ[C9a] [C9a] - Concentration of active caspase-9.
d[CEz]
dt
= bEz −
9∑
w=8
rwEa − µ[CEz] [CEz] - Concentration of executioner pro-
caspase.
d[CEa]
dt
=
9∑
w=8
rwEa − µ[CEa]− rIAP [CEa] - Concentration of active execu-
tioner caspase.
d[B2]
dt
= bB2 − µ[B2] [B2] - Concentration of Bcl-2.
d[Bx]
dt
= bBx − µ[Bx] [B2] - Concentration of Bcl-XL.
d[I8]
dt
= bI8 − µ[I8] [I8] - Concentration of FLIPs.
d[I9]
dt
= bI9 − µ[I9] [I9] - Concentration of ARC.
Huber et al. Equations [48] Variables
∂Cn(x, t)
∂t
=
∂2Cn(x, t)
∂x2
+ vn(x, t) Cn(x, t) - concentration of a given protein
(n=1,2,..,23)
vn(x, t) - Chemical reactions given by
usual Mass/Kinetic action.
Table 3. Equations for Mitochondrial Models.
and ATP to combine into apoptosome and cleave procapase-9 forming the initia-
tor caspase-9; cleavage of procaspase-3 by caspase-9 then forms the executioner
caspase-3 which in turn activates executioner caspase-6,7 and creates a positive
feedback loop by cleaving more caspase-9. These executioners finalize the death of
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the cell [30, 48, 77]. Apoptosis will not occur if threshold levels of effector capases
are not reached [30,48,77].
Extrinsic apoptosis occurs when an extracellular self-destruct order is given.
Stressed cells signal macrophages to engage with apoptotic cells through phago-
cytosis as a protective mechanism. Extracellular death ligands act as messagers
of these orders by binding with FAS (CD95) death receptors. Subsequently, FAS
receptors cluster allowing the binding with FADD (FAS-associated death domain).
Recruited by FADD, multiple procapase-8 compile and mutually cleave forming
capase-8. This new protein cleaves pro-apoptotic, BH3-only protein Bid forming
tBid (Truncated Bid). These interactions lead up to MOMP activation and sub-
sequent cascade; the MOMP activation pathway bridges extrinsic and intrinsic
apoptosis. Multidomain proteins are activated by apoptotic tBid activation, which
can be inhibited due to protective Bcl-2 proteins [30,77].
Fussenegger et al. (2000) [30] proposed a model simulating apoptosis to study
caspase activation and inhibition (See Table 3). The model confirms experimen-
tal observations that Bcl-2 above a critical level effectively inhibits procaspase-9
activation but fails to adequately inhibit procaspase-8 activation, and suppression
of FADD’s binding to FAS/FASL complex blocks caspase-8 activation but has lit-
tle effect on caspase-9 activation. The model assumes isotropic reactions with a
well mixed single domain and omits proteins including Bid/tBid, reactions like
caspase-8 cleaving of Bid, and bundles executioner caspases 3,6,7 into a single vari-
able. Furthermore, intrinsic and extrinsic apoptosis were not distinguished. Since
Fussenegger et al., several models have been proffered to redress omissions.
Albeck et al. (2008) [2, 3] introduced a model concentrating on the extrinsic
apoptosis death switch as well as MOMP interactions. The model represents both
cytosol and mitochondria as two separate domains interacting after MOMP with
parameters trained by live-cell imaging of HeLa cells. Similar to Fussenegger et al.,
Albeck et al. bundles many proteins with similar properties – such as caspase-8 and
-10 are represented as a single variable C8 – to simplify the model and all reactions
are isotropic. However, unlike the previous model, Albeck et al. incorporates a time
delay mechanism to compensate for the delay of death ligand reception to MOMP
as oppose to the quick death of the cell post-MOMP. Intriguingly, western blot
fails to show enough XIAP pre-MOMP to properly inhibit caspase-3. Albeck et al.
concluded that another protein/reaction must exist to account for this discrepancy.
The model did confirm that MOMP occurs after proapoptotic Bcl-2 proteins reach
a certain level depended on the physiological state of the cell. An alternate stable
state – partial cell death – is predicted by the model.
To eliminate the isotropic assumption, Huber et al. (2010) [48] combined pre-
vious models with one-dimensional diffusion PDEs. The typical mass reactions
and kinetics are extended by a PDE (Table 3) where vn(x, t) is the chemical reac-
tions. Although their goal was to investigate anistropic reactions in MOMP, the
reaction-diffusion equations remain applicable to wider studies.
3. Cellular Models
3.1. Immunology. Major players in DMD immune response are macrophages and
cytotoxic T cells. Macrophages are innate immune system members that lie in wait
within mucous membranes, activated by the presence of foreign species in the body.
Activated M1 macrophages are phagocytes that engulf these species as a threat to
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tissues and organs; they initiate the inflammatory response responsible for further
recruitment as needed. The adaptive immune system is activated post-phagocytosis
when macrophages present antigens to corresponding helper T cells. Helper T cells
coordinate an immune response to recruit members such as Cytotoxic T cells. These
initiate extrinsic apoptosis (Section 2.2 ), targeting damaged cells that display Class
I MHC markers which indicate a threat to healthy peers. Cytotoxic T cells inject
granzymes that destroy the targeted cell. Neutralization of the threat in a healthy
immune response occurs at a threshold; M2 macrophages promote tissue repair due
to damage caused by the inflammatory response [6, 68,91].
Two models have been proposed using a predator-prey system to mathemati-
cally model damage induced immune response in DMD, employing a log-normal
distribution:
(1) α(t) =
h
tσ
√
2pi
e
−(ln (t)−m)2
2σ2
to analyze initial damage. Both models utilize concentrations of the previously
listed immune response helpers in addition to concentrations of healthy, damaged,
and regenerating muscle cells. Dell’Acqua and Castiglione (2009) [23] is generated
by five ODEs in addition to a conservation law (Equations 2) describing the immune
response of DMD in the mice model. They used COPASI’s optimization methods
on experimental mdx mice data from Hoops et al. (2006) [46] to find the best fit
parameters. The set of equations used is
dM
dt
= bm + k1MD − dMM,
dH
dt
= bH + k2MD − dHH,
dC
dt
= k2HD − dCC,
dN
dt
= k4R− k5CN − α(t)N,
dD
dt
= k5CN − k6MD − dDD + α(t)N,
100 = N +D +R,(2)
where M = concentration of macrophages; H = concentration of CD4+; C =
concentration of CD8+; N = percentage of normal muscle fibers; D = percentage
of damaged muscle fibers; R = percentage of regenerating muscle fibers.
Jarrah et al. (2014) [51] (Equations 3) refines Dell’Acqua-Castiglione’s model by
adding an additional ODE which allows the conservation law to be implicit. The
parameters of this model were derived from recent experimental data of mdx mice.
Both models assume that the missing dystrophin in the muscle causes damaged
muscle cells to initiate the immune response which contributes to their own damage
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until eventual apoptosis. The set of equations used is
dM
dt
= bm + k1MD − dMM,
dH
dt
= bH + k2MD − dHH,
dC
dt
= bC + k2HD − dCC,
dN
dt
= k4R− k5CN − α(t)N,
dD
dt
= k5CN − k6MD − dDD + α(t)N,
dR
dt
= k6MD + dDD − k4R,(3)
and the definition of variables is the same as Equation 2. Initial conditions have
levels of cytotoxic T cell levels at 0; this changes when the impulse damage rep-
resented by equation 1 sets the system into motion. When h = 0, the impulse
damage is negated and the system remains in a stable state; allowing h > 0, the
model ensures that T helper cells draw cytotoxic T cells to the damaged region.
Damage caused by the immune system reaches a peak in weeks four through eight
until the presence of the players wanes. By week twelve, the decreased presence of
macrophages, CD4+ and CD8+ T cells (week fourteen) results in diminished levels
of degeneration and restoration.
Both models display regions of bistability. Depending on the initial damaged
caused and M0, the system collapses to healthy muscle stability or approaches
a stability with heterogeneous mixtures of healthy and damaged muscle. This
suggests that immune response to muscle damage could be a major contributor to
DMD’s pathophysiology [23,51] which has been shown experimentally [89,103].
Both Dell’Acqua-Castiglione and Jarrah et al. models are a broad overview of the
processes involved and leave out several proteins, signal pathways, and reactions.
Cytotoxic T cells act as the only non-impulse perpetrator of muscle damage in both
models yet fail to elucidate on the mechanics on which cytotoxic T cells cause the
damage. Extrinsic apoptosis caused by cytotoxic T cells has been proposed as a
possible path [90].
These models indicate that the strength of the immune response and maintenance
of the positive feedback system relies upon moving past these threshold points to
enter another stability state. Driving the system into these recovery regions could
prove to be a potential therapeutic target for redressing the role of the inflammatory
response.
3.2. Muscle Models. One muscle cell contains thousands of sarcomeres interlaced
and primed for contraction. A single sarcomere is made up of parallel thin and
thick filaments called actin and myosin; these entwined filaments pull on each other
during contraction [39,49]. MD leaves muscles vulnerable to unhealthy contraction
which exacerbates damage in a cycle that proves catastrophic to muscle cells even
in healthy populations. For diseased muscle, intense activity takes everyday, hourly
forms perpetuating MD progression [19,26].
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Figure 2. Sarcomere Regional Classification.
We can classify the regions of the sarcomere to better understand contraction
mechanics. The A band is made up of thick myosin filaments; throughout contrac-
tion its length remains constant centrally localized to the H zone. Actin filaments
are laced with the protein tropomyosin. At rest, tropomyosin covers the hinges that
catch on actin. Alternatively, the I band is composed of thin actin filaments that
alter its length between myosin filament pairs. Structures called Z discs fetter actin
filaments at their opposite ends [39,49]. In S1 regions, myosin edges are hinged and
highly flexible, catching on actin and releasing in an indefinite binding cycle (Figure
2). Upon their release, myosin filaments perform a power stroke catalyzed by the
hydrolysis of ATP. ATP is the means for crossbrige formation; it is the release of
phosphate during ATP hydrolysis that contracts the S1 region [39, 49]. Calcium
provides the means for binding whereas ATP drives contraction. Upon the release
of calcium, the protein troponin pushes the tropomyosin to expose binding sites
for actin. Upon exposure and a threshold level of ATP expression, the contraction
cycle begins [59].
Huxley (1957) [50] proposed an early mathematical description of this power
stroke process. Distance from binding site to crossbridge is taken as the independent
variable while function n(x, t) is the probability of a crossbridge being bound at
position x at time t. This yields a conservation law of:
(4)
∂n
∂t
− v(t)∂n
∂x
= (1− n)f(x)− ng(x).
The rate of energy release, φ, by ATP is:
(5) φ = ρ
∫ ∞
−∞
(1− n(x, t))f(x) dx
where ρ is the number of crossbridges at x, and  is the energy released by a single
crossbridge. This model captures the key physiological properties of crossbridges
but fails to illuminate the biochemical interactions; Pate (1989) [72] proposed a
model based on the Huxley model rectifying the biochemical interaction issue.
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Nuclear lamina deficiencies are linked with cytoskeletal defects in muscle cells
[85,92]. Destabilized DGC due to cytoskeletal compromise within the plasma mem-
brane leads to the aggregation of mechanical stress in contracting muscle cells [58].
Histology in lamina deficient diseases commonly presents with maligned and inter-
nalized nuclei in muscle fibers [85, 92]. Chronically strained A/C deficient lamins
result in cells experience higher rates of apoptosis [58,76]. Intriguingly, regenerating
muscle fibers also share high levels of internalized nuclei- the distinction between
pathology and regeneration is unclear presently [85].
Lammerding et al. (2004) [58] modeled nuclear misalignment and cytoskeletal
stress in lamin A/C-deficient mouse embryo fibroblasts. A/C lamins form compart-
ments for splicing factors as well as RNA polymerase II transcription. Inhibition of
A/C laminis suppresses RNA polymerase II-dependent transcription in mammalian
cells, while its as a scaffold in nuclear compartments remain unknown. A sinusoidal
force with amplitude 0.6 nanonewtons (nN) and with frequency 1 Hz, offset 0.6 nN,
was applied through a magnetic trap. Cylindrical coordinates (r, θ) were used to
measure bead displacement with the magnetic bead at the origin and θ = 0 for the
force direction. The equation represents the induced strain field described by the
analytic cell mechanics model proposed by Bausch et al. (1998) [9] ur is the radial
component of the induced bead displacement as a function of the applied force, F,
cell stiffness µ∗ the characteristic cut of radius κ−1, the distance from the magnetic
bead center r, and the polar angle θ.
(6) ur(r) =
F
2piµ∗
(
cos(θ)
3(1− σ)
4
K0(κ1r)− K1(κr)
κr
+
√
(1− σ)
2
K1(κ1r)
κr
)
K0 and K1 are modified Bessel functions of respective order 0 and 1 with
(7) K1(r) = κ
(
(1− σ)
2
)1/2
Fitting bead displacement data to equation 6, parameters µ∗ and κ can be obtained
letting σ = 0.5 and metallic bead contact radius of 2 µm.
In this model, the cytoskeleton was exposed to the same biaxial strain as the
membrane; for each cell type, nuclear deformation increased approximately linearly
with applied membrane strain. Both lamin A/C deficient cells result in decreased
nuclear stiffness and altered nuclear mechanics. Under resting conditions, they
found that the integrity of the nuclear envelope was maintained in A/C deficient
cells. However, under pressure, the control cells maintained nuclei integrity far more
than lamin deficient cells, though both could be ruptured. Increased vulnerability of
A/C deficient cells to mechanical stress comparatively was also concluded, with an
increase in both necrotic and apoptic cell fraction [58]. Necrosis mediated through
nuclear rupture is not wholly attributed to vulnerability to mechanical stimulation
in this model; only about 3-5% of A/C deficient nuclei ruptured.
There are limitations with mdx mice models to study eccentric contraction in
limb muscles, as mice models of the disease resemble degeneration patterns most
closely with human diaphragmatic muscles. Modeling gait progression as it relates
to degeneration in human dystrophic muscle is essential for quantifying damage due
to the cyclic activation of the immune system due to eccentric contractions [73].
Levels of healthy isometric force production can be maintained under the strain
of intense activity. Rest commenced with the buffering of calcium levels in the
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cytosol reduces mechanical stress to a point; inappropriate high or low levels of
activity leave muscles vulnerable to damage. Furthermore, both types of activity
are associated with increased levels of cytosolic calcium additionally linked with
fiber damage and apoptosis [73].
A.V. Hill (1938) [41] created a Force-Velocity relationship model to understand
isotonic and isometric muscle contractions; his work provides a basis for multibody,
dynamic musculoskeletal modeling and simulation. Hill’s model relates rate of
muscle contraction (shortening length), v, to the load p by:
(8) (p+ a)v = b(p0 − p)
for constants a and b given by experimental data and p0 is the isometric force.
Although Jewell and Wilkie (1958) [52] demonstrated that this model lost accuracy
when exposed to sudden changes to muscle length, Hill’s model remains pivotal and
is integrated in many other models.
Van der Linden et al. (1998) attempted whole tissue interaction simulations
examining aponeurosis/muscle under stress, limited by computational power, they
were restricted to 2D and simplified 3D models [100] [99]. Johansson et al. (2000)
[53] improved upon van Leeuwan-Kier’s (1997) [101] model of squid tentacles by
separately modeling active muscle attributes with Hill’s force-velocity model and de-
scribing passive elements as a hyperelastic material. Unfortunately since they used
parameter values based on van Leeuwan-Kier’s research and ANSYS, Johansson
et al. failed to significantly improve upon the predictions made by van Leeuwan-
Kier. Yucesoy et al. (2002) [108] introduced a similar model expanding on Van
der Linden’s work. Like Johansson et al., Yucesoy et al. separated muscle into
the extracellular matrix (passive) and myofiber (active); from that they created a
linked fiber-matrix mesh that fuses a passive element and an active element. This
“two domain” approach allowed a glimpse into the interaction of muscle fibers and
the extracellular matrix.
In an effort to understand the effects of geometries on muscle tissue, Sharafi
and Blemker (2010) [87] devised a model where actual rabbit muscle biopsies were
estimated with linear functions. They captured both the geometries of fibers (mi-
croscopic level) as well as the fascicles (macroscopic). Since they were modeling
muscle stress, Sharafi-Blemker only modeled the passive elements of muscle which
were described as a hyperelastic, nearly incompressible material. In opposition to
assumptions made by earlier modelists, Sharafi-Blemker discovered that fascicle
display anisotropic characteristics. Incorporating these geometries, Virgilio et al.
(2015) [102] created a simulation to study the effects of various disease patholo-
gies including MD. The simulation uses an agent based system to create fascicle
geometry with the addition of fibrosis and fatty tissue infiltration followed by the
use of micromechanical model described by Sharafi and Blemker. This model inde-
pendently verified the results that fibrosis aggravates the symptoms of DMD using
only in silico methods.
MD patients can experience higher-degree of ankle plantarflexion due to con-
tractures; “toe-walking” makes plantar flexor muscles such as the gastrocnemius,
soleus and peroneus therapeutic targets. Although the model concerns with long
term use of high heels, Zo¨llner’s model (2015) [109] could be use to describe toe-
walking in MD. Due to removal of sarcomere, fascicle shortens with long term toe
walking causing less than optimal motion range and increased stress. Healing of
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damaged muscle fibers occurs upon the fusing of differentiated myocytes alongside
the damaged fibers [73].
4. Areas of Future Quantitative Research
Characterizing pathology and pathogenesis of MD requires further study; future
models could accelerate therapeutic discovery by testing potential pathways in silico
as well as detecting new therapeutic pathways. There are areas for computational
research that have not yet been explored mathematically. These pathways may be
worthwhile exploring to better understand MD disease development and providing
treatments that may delay onset or progression.
The creation of rAAV/AAV1 (Recombinant Adeno-associated virus, Adeno-
associated virus 1) delivery system and CRISPR/Cas system indicates the pos-
sibility of a genetic cure for MD [63, 75]. Heller et al. (2015) [40] overexpressed
the human α7 integrin Gene, ITGA7, using the AAV1 delivery system in mdx
mice. ITGA7 is a skeletal muscle laminin receptor (Figure 1) whose overexpression
does not cause an immune response in mdx mice. Protective benefits of the DGC
were restored with ITGA7 overexpression; lifespans were also prolonged. Xu et al.
(2015) [107] used CRIPSR/Cas9 to remove mutated exon 23 with the dystrophin
genomic region to restore dystrophin expression in the DGC of mdx mice. Clini-
cal trials are currently taking place for LGMD2D [67]. Mendell et al. (2012) [66]
wrote a review outlining future work in gene therapy. Both systems require a rel-
atively small number of injection sites. Population dispersion models and GRNs
could help in the development and effective administration of both rAAV/AAV1
and CRISPR/Cas systems. Population dispersion and diffusion models could be
used to predict the outcome from a series of injections to the spread of the corrected
genes throughout the body. Potentially, these models could indicate the most ef-
fective injection sites. Beyond the correction of defective genes, both systems could
target genes that promote muscle growth and regeneration [78]. GRNs may help in
developing new therapies by finding pathways that both system could target and
thereby accelerate the body’s muscle regeneration. These types of treatments could
be applicable to both MD patients and in sports medicine.
Myostatin – a TGF-β (Section 3.1 ) protein – has long been recognized as a pos-
sible therapeutic option for MD. Early murine testing for several MD phenotypes
produced mixed results. For DMD (mdx mice) and LGMD2F (scgd−/− mouse),
Parsons et al. (2006) [71] concluded positive results for mice treated early in de-
velopment before widespread necrosis occurred. Treating sgcg−/− mice (model-
ing LGMD2C) resulted in positive muscle physiology including increase fiber size,
muscle mass, and grip force in addition to reduce frequency of apoptosis; how-
ever, muscle histology remained unfazed signifying lack of pathology change [12].
A possible solution proposed by Rodino-Klapac (2009) used AAV1 to genetically
edit Follistatin (the major myostatin inhibitor). A few experiments show that the
new treatment has few side effects and shows similar improvements as other myo-
statin inhibitors in LGMD2A (Calpainopathy). Future research is needed to show
if myostatin inhibition is a means to maintain pathophysiology in MD patients [78].
GRNs and physiological muscle models could be used to understand effective us-
age of myostatin. GRNs could discover new inhibitors and enzyme activators of
myostatin; this may allow targeted genetic editing to regulate myostatin similar
to Rodino-Klapac (2009) [78]. GRNs might also explain why these methods will
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work with some types of MD but fail with other types. Physiological models may
demonstrate the increase in fiber size, muscle mass, and grip force due to myostatin
therapies.
A plethora of models could be used to describe cellular, molecular, and phar-
maceutical interactions of the immune system. Precise molecular, mathematical
models bridging arginine metabolism with oscillations in macrophage phenotypic
expression could be used to model nitric oxide mediated cytotoxicity as well as
fibrosis during satellite cell proliferation. Mechanical models for macrophage infil-
tration and molecular models for macrophage phenotype oscillation could also be
useful to better characterize chronic immune system activation due to structural
defects. Integration into musculoskeletal simulation may be useful to model the im-
munological role in MD pathogenesis and progression. Agent based models could
be used to imitate immune cells.
MD disease progression also results in alterations to pathophysiology such as gait
and muscle atrophy. Noninvasive studies with patients, especially children, could be
critical to create a staged model for gait devolution and morphology. Quantifying
degrees of eccentric contraction using musculoskeletal simulation could possibly
explain selective degeneration in DMD [47].
5. Discussion
With new developments in computational power and data availability, a growing
amount of research is using a systems biology approach to understand pathogenesis
and progression of disease. Effective and integrated in vitro and in silico mod-
els could inform biological phenomena, even without the need of a living subject.
For instance, over the last few decades, collagen hydrogel with muscle derived cells
(CHMDCs) have promised to revolutionize in vitro experiments and tissue engineer-
ing. For CHMDCs to reach the envisioned use, verification by use of mathemati-
cal simulations are needed. Recently while examining shape and design, Hodgson
(2015) [42] used a combination finite elements and agent based analysis to illustrate
the lines of principle strain and cell migration in CHMDCs confirming earlier in
vitro work by Smith et al. (2012) [88]. As MD is a rare disorder, the use of mathe-
matical models could help elucidate the underlining mechanisms of the disease that
might not be easily detectable given the limited subject pool.
Although genetic studies have implicated genes as the cause of many types of
MD, relatively little is know about about common pathways between these genes
that may affect pathogenesis and create similar phenotypes; this necessitates the use
of mathematical models describing GRNs (Section 2.1 ). Common genes like Dik1,
Dusp13, and Casq2 [98] and there downstream pathways provide future prospects
for therapeutic intervention.
Mitochondrial and immunological mechanisms further MD progression. Mathe-
matical models of apoptosis and mitochondrial fission/fusion help to understand in-
tracellular processes that directly affect cellular vitality and death. Tam et al. [93]’s
mitochondrial fission/fusion model related mitochondrial health with nuclear mech-
anisms to rescue mutated mtDNA; unhealthy mitochondria can trigger intrinsic
apoptosis with the release of cytochrome c. Fusseneger et al. [30] and Albeck et
al. [2, 3] furthered the study of apoptotic mechanics by creating models to sim-
ulate the processes; both models agree with already published results. Extrinsic
apoptosis can be signaled by immune cells. Immunological mathematical models
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display a larger view of cellular interactions that bridge the gap of molecular actions
and tissue level muscle damage. Damage caused by stress and weakened cellular
structure is repaired and debris removed by extrinsic apoptosis and phagocytosis.
Dell’Acqua and Castiglione [23] and Jarrah et al. [51] created models describing the
cellular/tissue interactions of a few immune cells.
Mathematical models of muscles under contractile stress are essential to un-
derstanding the long term development of most types of MD. Partial differential
equations and agent based models of anisotropic strain from contraction display
where cellular rupture and immune response will likely occur. Physical therapeutic
and pharmaceutical interventions can be targeted to such areas of high stress to
stymie MD progression. Expanding cellular models of the immune response and
combining with molecular signals could create a more comprehensive view of muscle
tissue regeneration and damage caused by chronic inflammation. Future research
could incorporate multiple levels of models into a unified simulation to give a whole
view of the progression of MD.
Outside of MD, immunological, mitochondrial, and genetic components cov-
ered in this review play a role in diseases with higher rates of prevalence such
as Alzheimer’s [74], Parkinson’s [106], cancer [74] and ALS [21]. Aforementioned
diseases have strong ties to mitochondrial dysfunction and inflammatory responses
that similarly exacerbate disease pathogenesis and subsequent progression. Even
the (relatively) benign aging process is associated with mitochondrial dysfunc-
tion [57]. All enact a financial and emotional cost for those affected and their
families. Future research that sheds light on MD disease dynamics, which is likely
to occur through mathematical modeling, will provide the means to engage and
perhaps ultimately bypass biological systems coordinating together to exacerbate
degeneration.
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